| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
microRNA 374b | 0.621 | 0.500 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
microRNA 874 | 0.628 | 0.577 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | |||||||||
|
SOD2 overlapping transcript 1 | 0.722 | 0.500 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 1995 | 1995 | |||||||||
|
Endometriosis, susceptibility to, 1 | 0.890 | 0.269 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
microRNA 1247 | 0.604 | 0.500 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | |||||||||
|
FAS antisense RNA 1 | 0.695 | 0.538 |
|
group | 0.010 | None | < 0.001 | 1 | 0 | 2017 | 2017 | |||||||||
|
mastermind like domain containing 1 | 0.650 | 0.500 | 0.63 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2007 | 2007 | ||||||||
|
MT-RNR2 like 8 | 1.000 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | ||||||||||
|
apelin receptor early endogenous ligand | 0.792 | 0.346 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
RBM14-RBM4 readthrough | 0.647 | 0.615 | 0.98 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2018 | 2018 | ||||||||
|
dynamin 1 like | 0.475 | 0.808 | 5.7E-04 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2018 | 2018 | ||||||||
|
nuclear receptor subfamily 1 group H member 3 | 0.566 | 0.692 | 0.90 |
|
group | 0.010 | None | 1.000 | 1 | 1 | 2015 | 2015 | ||||||||
|
papillary thyroid carcinoma susceptibility candidate 3 | 0.722 | 0.385 |
|
group | 0.010 | None | 1.000 | 1 | 2 | 2016 | 2016 | |||||||||
|
PGR antisense RNA 1 | 0.514 | 0.808 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | |||||||||
|
opsin 1, medium wave sensitive 3 | 0.601 | 0.769 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
nicotinamide phosphoribosyltransferase | 0.502 | 0.808 | 0.98 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | ||||||||
|
FERM, ARH/RhoGEF and pleckstrin domain protein 1 | 0.769 | 0.231 | 5.1E-06 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2015 | 2015 | ||||||||
|
E2F1 mRNA stabilizing lncRNA | 0.695 | 0.500 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | |||||||||
|
ADAM metallopeptidase domain 10 | 0.489 | 0.846 | 1.00 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | ||||||||
|
tripartite motif containing 13 | 0.462 | 0.846 | 0.64 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2006 | 2006 | ||||||||
|
cyclin dependent kinase 2 associated protein 2 | 0.544 | 0.808 | 0.79 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2017 | 2017 | ||||||||
|
receptor activity modifying protein 2 | 0.626 | 0.654 | 5.1E-02 |
|
group | 0.010 | None | 1.000 | 1 | 1 | 2017 | 2017 | ||||||||
|
cyclin dependent kinase inhibitor 1B | 0.409 | 0.769 | 0.62 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2004 | 2004 | ||||||||
|
follistatin like 3 | 0.695 | 0.423 | 0.69 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2019 | 2019 | ||||||||
|
inactive glutathione hydrolase 2 | 0.559 | 0.731 |
|
group | 0.010 | None | 1.000 | 1 | 0 | 2006 | 2006 |